Cephradine[ (Velosef) ] Drug Information

Contains Cephradine drug information and provides Cephradine drug indication, contraindication, special concerns, side effects, overdose management and dosage
Search Drugs by Generic or Trade Name:
Browse Drugs by Generic Name:
[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z ]

List of Contents:
  • Indications
  • Contraindications
  • Special Concerns
  • Side Effects
  • Overdose Management
  • Dosage

  • Indications:
    Oral. (1) Respiratory tract infections (tonsillitis, pharyngitis, lobar pneumonia) due to Streptococcus pneumoniae and group A ?-hemolytic streptococci. (2) Otitis media due to group A ?-hemolytic streptococci, S. pneumoniae, Haemophilus influenzae, and staphylococci. (3) Skin and skin structure infections due to staphylococci (penicillinase/nonpencilliase-producing) and ?- streptococci. (4) UTIs (including prostatitis) due to Escherichia coli, Proteus mirabilis, and Klebsiella species.

    Parenteral. (1) Respiratory tract infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillinase/non-penicillinase-producing), and group A ?-hemolytic streptococci. (2) UTIs due to E. coli, P. mirabilis, and Klebsiella species. (3) Skin and skin structure infections due to S. aureus and group A ?-hemolytic streptococci. (4) Bone infections due to S. aureus. (5) Septicemia due to S. pneumoniae, S. aureus, P. mirabilis, and E. coli. (6) To prevent infections before, during, and after surgery for vaginal hysterectomy and other surgical procedures.
    Back to Top
    Contraindications:
    No Available information
    Back to Top
    Special Concerns:
    Safe use during pregnancy, of the parenteral form in infants under 1 month of age, and of the PO form in children less than 9 months of age have not been established.
    Back to Top
    Side Effects:
    No Available information
    Back to Top
    Overdose Management:
    No Available information
    Back to Top
    Drug Interactions:
    No Available information
    Back to Top
    Dosage:
    Capsules, Oral Suspension Skin and skin structures, respiratory tract infections (other than lobar pneumonia).

    Adults, usual: 250 mg q 6 hr or 500 mg q 12 hr.

    Lobar pneumonia.

    Adults: 500 mg q 6 hr or 1 g q 12 hr.

    Uncomplicated UTIs.

    Adults, usual: 500 mg q 12 hr.

    More serious UTIs and prostatitis.

    500 mg q 6 hr or 1 g q 12 hr (severe, chronic infections may require up to 1 g q 6 hr).

    Use in children.

    Pediatric, over 9 months: 25-50 mg/kg/day in equally divided doses q 6-12 hr (75-100 mg/kg/day for otitis media). Do not exceed 4 g/day.

    Deep IM, IV General infections.

    Adults: 2-4 g/day in equally divided doses q.i.d.

    Surgical prophylaxis.

    Adults: 1 g 30-90 min before surgery; then, 1 g q 4-6 hr for one to two doses (or up to 24 hr postoperatively).

    Cesarean section, prophylaxis.

    IV: 1 g when the umbilical cord is clamped; then, give two additional 1-g doses IV or IM 6 and 12 hr after the initial dose.

    Use in children.

    Pediatric, over 1 year: 50-100 mg/kg/day in equally divided doses q.i.d. Do not exceed adult dose.



    Note: For clients not on dialysis, use the following dosage in renal impairment: CCR, over 20 mL/min: 500 mg q 6 hr; CCR, 5-20 mL/min: 250 mg q 6 hr; CCR, less than 5 mL/min: 250 mg q 12 hr. For those on chronic, intermittent hemodialysis, give 250 mg initially; repeat at 12 hr and after 36-48 hr.
    Back to Top